Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma
Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Clinical Pearls
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
- 1-3 catheters co-deliver liposomal-irinotecan and gadolinium into a patient’s tumor.
- Gadolinium is used so that imaging can be done in real-time.
- This process is unique because it bypasses systemic toxicity and ensures that the drug is administered properly.
<<<
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Olaptesed Pegol Wins FDA Fast Track Designation in Brain Cancer
April 3rd 2024The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.
Read More
